These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38566987)

  • 1. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
    Nylund P; Nikkarinen A; Ek S; Glimelius I
    Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
    Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
    J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
    Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
    BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
    Nikkarinen A; Lokhande L; Amini RM; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
    Blood Adv; 2023 Sep; 7(18):5304-5313. PubMed ID: 37389827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
    J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
    Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
    Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
    Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Jain P; Wang ML
    Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
    Saleh K; Cheminant M; Chiron D; Burroni B; Ribrag V; Sarkozy C
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
    Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
    Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.
    de Matos Rodrigues J; Lokhande L; Olsson LM; Hassan M; Johansson A; Janská A; Kumar D; Schmidt L; Nikkarinen A; Hollander P; Glimelius I; Porwit A; Gerdtsson AS; Jerkeman M; Ek S
    Blood Adv; 2024 Aug; 8(16):4370-4385. PubMed ID: 38959399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
    Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
    J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Qualls D; Kumar A; Epstein-Peterson ZD
    Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.
    Li P; Yuan J; Ahmed FS; McHenry A; Fu K; Yu G; Cheng H; Xu ML; Rimm DL; Pan Z
    Front Oncol; 2021; 11():701492. PubMed ID: 34527580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.